Page 63 - Read Online

Mol Morphol 2002;10:139-46. activates Akt. Cancer Res 2006;66:1500-8.
78. Collaud S, Tischler V, Atanassoff A, Wiedl T, Komminoth P, 97. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum
Oehlschlegel C, Weder W, Soltermann A. Lung neuroendocrine D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody
tumors: correlation of ubiquitinylation 1 and sumoylation with to the insulin-like growth factor I receptor. Clin Cancer Res
nucleo-cytosolic partitioning of PTEN. BMC Cancer 2015;15:74. 2007;13:5549-55s.
79. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF 98. Anthony LB, Loehrer PJ, Leong S, Shah MH, Safran H, Senzer
system in cancer growth and metastasis: overview and recent NN, Zojwalla NJ, Youssoufian H. Phase II study of cixutumumab
insights. Endocr Rev 2007;28:20-47. (IMC-A12) plus depot octreotide for patients with metastatic
80. Furukawa M, Raffeld M, Mateo C, Sakamoto A, Moody TW, carcinoid or islet cell carcinoma. J Clin Oncol 2010;28;15s.
Ito T, Venzon DJ, Serrano J, Jensen RT. Increased expression of 99. Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong
insulin-like growth factor I and/or its receptor in gastrinomas is D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin
associated with low curability, increased growth, and development C, LoRusso P. Phase I Trial of Cixutumumab Combined with
of metastases. Clin Cancer Res 2005;11:3233-42. Temsirolimus in Patients with Advanced Cancer. Clin Cancer Res
81. Chaves J, Saif MW. IGF system in cancer: from bench to clinic. 2011;17:6052-60.
Anticancer Drugs 2011;22:206-12. 100. Rothenberg ML, Tolcher AW, Sarantopoulos J, Rodon J, Friberg
82. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf G, Deng H, McCafferey I, Hwang Y, Puzanov I. AMG 479
E, Wiedenmann B, Boehm BO, Adler G, Seufferlein T. Insulin- monotherapy to treat patients with advanced GI carcinoid tumors:
like growth factor-I is an autocrine regulator of chromogranin A a subset analysis from the first-in-human study. Presented at the
secretion and growth in human neuroendocrine tumor cells. Cancer ASCO Gastrointestinal Cancers Symposium, San Francisco,
Res 2000;60:4573-81. January 2009.
83. Nilsson O, Wangberg B, Theodorsson E, Skottner A, Ahlman 101. Strosberg JR, Chan JA, Ryan DP, Meyerhardt JA, Fuchs CS,
H. Presence of IGF-I in human midgut carcinoid tumours--an Abrams T, Regan E, Brady R, Weber J, Campos T, Kvols LK, Kulke
autocrine regulator of carcinoid tumour growth? Int J Cancer MH. A multi-institutional, phase II open-label study of ganitumab
1992;51:195-203. (AMG 479) in advanced carcinoid and pancreatic neuroendocrine
84. Nilsson O, Wangberg B, McRae A, Dahlstrom A, Ahlman H. tumors. Endocr Relat Cancer 2013;20:383-90.
Growth factors and carcinoid tumours. Acta Oncol 1993;32:115-24. 102. Sartelet H, Decaussin M, Devouassoux G. Nawrocki-Raby B,
85. Wulbrand U, Wied M, Zöfel P, Göke B, Arnold R, Fehmann H. Brichon PY, Brambilla C, Brambilla E. Expression of vascular
Growth factor receptor expression in human gastroenteropancreatic endothelial growth factor (VEGF) and its receptors (VEGF-R1 [Flt-
neuroendocrine tumours. Eur J Clin Invest 1998;28:1038-49. 1] and VEGF-R2 [KDR/Flk-1]) in tumor lets and in neuroendocrine
86. Höpfner M, Baradari V, Huether A, Schöfl C, Scherübl H. The cell hyperplasia of the lung. Hum Pathol 2004;35:1210-7.
insulin-like growth factor receptor 1 is a promising target for novel 103. Bertino EM, Confer PD, Colonna JE, Ross P, Otterson
treatment approaches in neuroendocrine gastrointestinal tumours. GA. Pulmonary neuroendocrine/carcinoid tumors. Cancer
Endocr Relat Cancer 2006;13:135-49. 2009;115:4434-41.
87. Vitale L, Lenzi L, Huntsman SA, Canaider S, Frabetti F, Casadei 104. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other
R, Facchin F, Carinci P, Zannotti M, Coppola D, Strippoli P. disease. Nat Med 1995;1:27-31.
Differential expression of alternatively spliced mRNA forms of 105. Berger DP, Herbstritt L, Dengler WA, Marmé D, Mertelsmann R,
the insulin-like growth factor 1 receptor in human neuroendocrine Fiebig HH. Vascular endothelial growth factor (VEGF) mRNA
tumours. Oncol Rep 2006;15:1249-56. expression in human tumour models of different histologies. Ann
88. Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan Oncol 1995;6:817-25.
AA, Anderson KC. Inhibition of heat shock protein 90 (HSP90) as a 106. Lawnicka H, Stepieñ H, Wyczółkowska J, Kolago B, Kunert-
therapeutic strategy for the treatment of myeloma and other cancers. Radek J, Komorowski J. Effect of somatostatin and octreotide on
Br J Haematol 2011;152:367-79. proliferation and vascular endothelial growth factor secretion from
89. Gloesenkamp C, Nitzsche B, Lim AR, Normant E, Vosburgh murine endothelial cell line (HECa10) culture. Biochem Biophys
E, Schrader M, Ocker M, Scherübl H, Höpfner M. Heat shock Res Commun 2000;268:567-71.
protein 90 is a promising target for effective growth inhibition 107. Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA,
of gastrointestinal neuroendocrine tumours. Int J Oncol Carter R, von Recum HA, Yuan J, Kamihara J, Flynn E, D’Amato R,
2012;40:1659-67. Folkman J, Mulligan RC. Comparative evaluation of the antitumour
90. Gilbert JA, Adhikari LJ, Lloyd RV, Halfdanarson TR, Muders MH, activity of antiangiogenic proteins delivered by gene transfer. Proc
Ames MM. Molecular markers for novel therapeutic strategies in Natl Acad Sci U S A 2001;98:4605-10.
pancreatic endocrine tumors. Pancreas 2013;42:411-21. 108. Matsumoto T, Claesson-Welsh L. VEGF receptor signal
91. Froesch ER, Schmid C, Schwander J, Zapf J. Actions of insulin-like transduction. Sci STKE 2001;2001:re21.
growth factors. Ann Rev Physiol 1985;47:443-67. 109. Klagsbrun M, Takashima S, Mamluk R. The role of neuropilin in
92. Schoenle E, Zapf J, Humbel RE, Froesch ER. Insulin-like growth vascular and tumour biology. Adv Exp Med Biol 2002;515:33-48.
factor I stimulates growth of hypophysectomised rats. Nature 110. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its
1982;296:252-3. receptors. Nat Med 2003;9:669-76.
93. Adams SO, Nissley SP, Handwerger S, Rechler MM. Developmental 111. Treiber G, Wex T, Röcken C, Fostitsch P, Malfertheiner P. Impact of
patterns of insulin-like growth factor-I and -II synthesis and biomarkers on disease survival and progression in patients treated
regulation in rat fibroblasts. Nature 1983;302:150-3. with octreotide for advanced hepatocellular carcinoma. J Cancer
94. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of Res Clin Oncol 2006;132:699-708.
rapamycin inhibitors activate the AKT kinase in multiple myeloma 112. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A,
cells by up-regulating the insulin-like growth factor receptor/insulin Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis
receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol A, Daskalopoulou D, Paraskevas E. Long acting octreotide in the
Cancer Ther 2005;4:1533-40. treatment of advanced hepatocellular cancer and overexpression of
95. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin somatostatin receptors: randomized placebo-controlled trial. World
induces feedback activation of Akt signaling through an IGF-1R- J Gastroenterol 2007;13:3164-70.
dependent mechanism. Oncogene 2007;26:1932-40. 113. Ho QT, Kuo CJ. Vascular endothelial growth factor: Biology and
96. O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, therapeutic applications. Int J Biochem Cell Biol 2007;39:1349-57.
Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N. mTOR 114. O’Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW,
inhibition induces upstream receptor tyrosine kinase signaling and Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC,
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 31, 2016 ¦ 339